Please complete the CAPTCHA to continue
@sublimitytherapeutics.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Andrew Williams is listed as CFO | COO | Founder | Company Builder at GoodCap Pharmaceuticals Inc., based in Greater Vancouver Metropolitan Area, Canada. AeroLeads shows a work email signal at sublimitytherapeutics.com and a matched LinkedIn profile for Andrew Williams.
Andrew Williams previously worked as Chief Financial Officer at Goodcap Pharmaceuticals Inc. and Chief Financial Officer + Seed Investor at Pattern Pharma. Andrew Williams holds Bachelor Of Arts, Honors, Economics from Queen'S University.
This section adds company-level context without repeating Andrew Williams's masked contact details.
AeroLeads found 1 current-domain work email signal for Andrew Williams. Compare company email patterns before reaching out.
Executive with 20+ years specializing in start-ups, capital raising, corporate governance, financial reporting, auditing, investor relations, risk management, go public transactions (NASDAQ and TSX) and M&A. Most notably, a member of the founding team and COO & CFO of Cynapsus Therapeutics, a specialty CNS pharmaceutical company that developed a sublingual thin film strip for the treatment of OFF episodes associated with Parkinson’s disease. In October 2016, Cynapsus was acquired for $841 million by Sunovion Pharmaceuticals, a wholly owned subsidiary of Sumitomo Dainippon Pharma. While serving as CFO, Cynapsus raised approximately $170 million via private and public offerings, completed a go public transaction to list on the Toronto Venture Exchange (TSX-V), uplisted to the Toronto Stock Exchange (TSX), and closed a $90 million US Initial Public Offering (Re-IPO) and concurrent listing on NASDAQ. Hold an MBA from Ivey Business School (Western) and a BAH in Economics from Queen's University.
Listed skills include Strategic Planning, Finance, Strategy, Business Strategy, and 10 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Toronto, Ca
Goodcap is an early stage life sciences company developing therapies to improve brain and mental health by combatting neuroinflammation. GoodCap’s lead drug candidate, GCAP001, combines two active molecules that work synergistically to reduce key inflammatory biomarkers and symptoms associated with PTSD, depression and other mental health disorders.
Toronto, Ontario, Ca
Pattern is a biotechnology company focused developing therapies that mobilize innate immunity to address immune failures underpinning a wide range of infectious diseases and cancers. Pattern’s lead asset, PPI-100, is a TLR4 agonist that activates dendritic cells (DCs) and macrophages, causing them to become killer DCs and killer macrophages, which in turn activate NK cells. PPI-100 is first being developed in the perioperative setting to address the 40% relapse rate in cancer patients 5 years after surgical resection.
San Diego, California, Us
Mesa is a San Diego-based healthcare test and data company that developed the Accula System, an affordable, easy-to-use, point-of-care PCR-based testing platform for infectious disease diagnosis. The platform enables rapid, highly accurate testing at physician offices, pharmacies and other settings, providing results in 30 minutes. Beyond COVID-19 testing, Mesa Biotech's existing platform includes tests for flu, respiratory syncytial virus (RSV), and Strep A.In February 2021, Thermo Fisher acquired Mesa for $550 million: https://www.fiercebiotech.com/medtech/thermo-fisher-nets-handheld-covid-19-test-maker-mesa-biotech-550m-deal
Dublin, 11, Ie
Sublimity was a Dublin-based clinical stage pharmaceutical company developing therapies for gastrointestinal and immunological diseases. Sublimity’s lead asset, ST-0529, was in Phase 2b studies for the treatment of moderate-to-severe ulcerative colitis.
Cynapsus was a specialty CNS pharmaceutical company that developed a fast-acting, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson's disease. Responsible for Cynapsus' public company operations on TSX and NASDAQ, including regulatory, compliance, legal, finance, accounting and administrative functions. In capacity as CFO, supervised the controller, treasury, tax, audit, insurance, information technology and security, investor relations and facilities functions. Also worked closely with the Board of Directors, Audit Committee, Corporate Governance, Nominating and Compensation Committee, and Special Committee of the Board. While acting as CFO, Cynapsus raised approximately $170 million primarily via private placements and public offerings, including a $90 million re-US IPO and NASDAQ listing. Cynapsus also received two grants from The Michael J. Fox Foundation for Parkinson's Research, the world’s largest non-profit funder of Parkinson’s research.In October 2016, Cynapsus was acquired for $841 million (all cash) by Sunovion Pharmaceuticals, a wholly owned subsidiary of Sumitomo Dainippon Pharma: https://www.businesswire.com/news/home/20160831006494/en/Sunovion-Pharmaceuticals-Acquire-Cynapsus-Therapeutics
Quick answers generated from the profile data available on this page.
Andrew Williams works for GoodCap Pharmaceuticals Inc..
Andrew Williams is listed as CFO | COO | Founder | Company Builder at GoodCap Pharmaceuticals Inc..
AeroLeads has found 1 work email signal at @sublimitytherapeutics.com for Andrew Williams at GoodCap Pharmaceuticals Inc..
Andrew Williams is based in Greater Vancouver Metropolitan Area, Canada while working with GoodCap Pharmaceuticals Inc..
Andrew Williams has worked for Goodcap Pharmaceuticals Inc., Pattern Pharma, Mesa Biotech, Inc., Sublimity Therapeutics, and Cynapsus Therapeutics.
You can use AeroLeads to view verified contact signals for Andrew Williams at GoodCap Pharmaceuticals Inc., including work email, phone, and LinkedIn data when available.
Andrew Williams holds Bachelor Of Arts, Honors, Economics from Queen'S University.
Andrew Williams is listed with skills including Strategic Planning, Finance, Strategy, Business Strategy, Mergers And Acquisitions, Financial Modeling, Due Diligence, and Business Development.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts